Monthly Archives: September 2012

ProLung names Clark Campbell as Chairman of the Board

September 11, 2012, Salt Lake City, Utah—The medical technology company, ProLung, today announced the naming current board member Clark A. Campbell, Ph.D. as its new Chairman, replacing William A. Fresh, who continues as a Director. Campbell steps into this role as the company makes preparations to market the ProLung Test, a new tool in the early detection of lung cancer. Studies have shown that the test immediately and accurately identifies malignancy in patients who have been found to have an indeterminate lung mass. This can help solve the crucial problem of late detection, a major factor in lung cancer’s high mortality rate. “Dr. Campbell’s project management expertise will be invaluable as we embark on the final stages of preparing the ProLung Test for U.S. and international markets,” said Steven C. Eror, president and CEO of ProLung. “We’re fortunate to have him join us in our efforts to help give lung cancer patients a better chance for survival.”

By |12 September 2012|Press|Comments Off on ProLung names Clark Campbell as Chairman of the Board|

Freshmedx announces name change to ProLung,TM underscoring its focus on the deadliest of cancers

September 11, 2012, Salt Lake City, Utah—Freshmedx today announced its intention to do business as ProLung, as it continues to commercialize the ProLung Test, a new tool in the early detection of lung cancer. According to company president Steven C. Eror, “The ProLung name expresses the hope this new test brings to the battle against the deadliest of all cancers. Studies have shown this new technology to be a major step forward in helping to solve the problems of late detection and difficult diagnosis, the main causes of lung cancer’s high mortality rate. ProLung reflects our commitment to promote lung health and improve outcomes for lung cancer patients.”

By |10 September 2012|Press|Comments Off on Freshmedx announces name change to ProLung,TM underscoring its focus on the deadliest of cancers|